open access

Vol 21, No 1 (2017)
Editorial
Published online: 2017-03-29
Get Citation

Inhibitor konwertazy angiotensyny z antagonistą wapnia trzeciej generacji — nowy lek złożony w terapii hipotensyjnej. Stanowisko ekspertów

Filip M. Szymański, Krystyna Widecka, Krzysztof Narkiewicz, Andrzej Tykarski, Krzysztof J. Filipiak
DOI: 10.5603/AH.2017.0003
·
Arterial Hypertension 2017;21(1):18-28.

open access

Vol 21, No 1 (2017)
Editorial
Published online: 2017-03-29

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Inhibitor konwertazy angiotensyny z antagonistą wapnia trzeciej generacji — nowy lek złożony w terapii hipotensyjnej. Stanowisko ekspertów

Journal

Arterial Hypertension

Issue

Vol 21, No 1 (2017)

Pages

18-28

Published online

2017-03-29

DOI

10.5603/AH.2017.0003

Bibliographic record

Arterial Hypertension 2017;21(1):18-28.

Authors

Filip M. Szymański
Krystyna Widecka
Krzysztof Narkiewicz
Andrzej Tykarski
Krzysztof J. Filipiak

References (32)
  1. Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016; 37(42): 3232–3245.
  2. Zdrojewski T, Bandosz P, Rutkowski M, et al. Rozpowszechnienie, wykrywanie i skuteczność leczenia nadciśnienia tętniczego w Polsce - wyniki badania NATPOL 2011. Nadciśnienie Tętnicze. 2014; 18: 116–117.
  3. Widecka K, Grodzicki T, Narkiewicz K, et al. Zasady postępowania w nadciśnieniu tętniczym - 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Arterial Hypertens. 2011; 15: 55–82.
  4. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009; 122(3): 290–300.
  5. Rosenthal T, Gavras I, Gavras I, et al. Combination therapy as first-line treatment for hypertension. Curr Hypertens Rep. 2004; 6(4): 267–272.
  6. Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366(9489): 895–906.
  7. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens. 2004; 22(8): 1453–1458.
  8. Makani H, Bangalore S, Romero J, et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011; 124(2): 128–135.
  9. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010; 55(2): 399–407.
  10. Hair PI, Scott LJ, Perry CM. Fixed-Dose Combination Lercanidipine/Enalapril. Drugs. 2007; 67(1): 95–106.
  11. Barrios V, Navarro A, Esteras A, et al. Investigators of ELYPSE Study (Eficacia de Lercanidipino y su Perfil de Seguridad). Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press. 2002; 11(2): 95–100.
  12. Soma MR, Natali M, Donetti E, et al. Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br J Pharmacol. 1998; 125(7): 1471–1476.
  13. Corsini A, Accomazzo MR, Canavesi M, et al. The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved? Blood Press Suppl. 1998; 2: 18–22.
  14. Rachmani R, Levi Z, Zadok BS, et al. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin Pharmacol Ther. 2002; 72(3): 302–307.
  15. Canavesi M, Baldini N, Leonardi A, et al. In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J Cardiovasc Pharmacol. 2004; 44(4): 416–422.
  16. Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs. 2003; 63(22): 2449–2472.
  17. Głuszek J, Pawlaczyk K. Działania niepożądane antagonistów wapnia. Choroby Serca i Naczyń. 2006; 3: 18–31.
  18. Fogari R, Malamani G, Zoppi A, et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel-group study. Current Therapeutic Research. 2000; 61(12): 850–862.
  19. Vasigar P, Batmanabane M. Anti-inflammatoryactivity of calciumchannel blocker lercanidipine hydrochloride. J Pharmacol Pharmacother. 2013; 4(4): 238–242.
  20. Rizzoni D, Porteri E, De Ciuceis C, et al. CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigators. Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1998; 32(5): 798–806.
  21. Hosomi N, Mizushige K, Ohyama H, et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke. 2001; 32(7): 1539–1545.
  22. Mancia G, Coca A, Chazova I, et al. FELT investigators. Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial. J Hypertens. 2014; 32(8): 1700–7; discussion 1707.
  23. Scholze J, Bramlage P, Trenkwalder P, et al. Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. Expert Opin Pharmacother. 2011; 12(18): 2771–2779.
  24. Puig JG, Calvo C, Luurila O, et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J Hum Hypertens. 2007; 21(12): 917–924.
  25. Barrios V, Escobar C, de la Figuera M, et al. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study. Cardiovasc Ther. 2008; 26(1): 2–9.
  26. Rump LC. Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension. Arzneimittelforschung. 2010; 60(3): 124–130.
  27. Derosa G, Bonaventura A, Romano D, et al. Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study. J Am Soc Hypertens. 2014; 8(6): 422–428.
  28. Derosa G, Bonaventura A, Romano D, et al. Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients. J Clin Pharm Ther. 2014; 39(3): 277–285.
  29. Ghiadoni L, Bruno RM, Cartoni G, et al. Combination therapy with lercanidipine and enalapril reduced central blood pressure augmentation in hypertensive patients with metabolic syndrome. Vascul Pharmacol. 2015 [Epub ahead of print].
  30. Egan CG, Pontremoli R. Role of the fixed-dose combination lercanidipine-enalapril in renal protection. J Nephrol. 2011; 24(4): 428–437.
  31. Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail. 2005; 27(1): 73–80.
  32. Angeloni E, Vitaterna A, Lombardo P, et al. Single-pill combination therapy in the initial treatment of marked hypertension: a propensity-matched analysis. Clin Exp Hypertens. 2015; 37(5): 404–410.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl